慢性鼻-鼻窦炎(chronic rhinosinusitis,CRS)是鼻腔及鼻窦黏膜的慢性炎症,包括慢性鼻-鼻窦炎不伴鼻息肉(chronic rhinosinusitis without nasal polyps,CRSsNP)和慢性鼻-鼻窦炎伴鼻息肉(chronic rhinosinusitis with nasal polyps,CRSw...慢性鼻-鼻窦炎(chronic rhinosinusitis,CRS)是鼻腔及鼻窦黏膜的慢性炎症,包括慢性鼻-鼻窦炎不伴鼻息肉(chronic rhinosinusitis without nasal polyps,CRSsNP)和慢性鼻-鼻窦炎伴鼻息肉(chronic rhinosinusitis with nasal polyps,CRSwNP)。中医治疗CRS主要包括:辨证论治、专方验方、中成药、针灸、耳穴贴压、中药鼻腔雾化和中药鼻腔冲洗、穴位按摩等;西医治疗主要包括糖皮质激素、抗生素、抗过敏药物、黏液溶解促排剂、手术治疗等。中西医结合治疗是目前治疗CRS的重要手段,但存在以下问题:相关临床文献较少,尚无临床指南,且中医药治疗CRS的作用机制还不明确。今后,需要行多中心、大样本的临床研究,进一步深入探讨中医药治疗CRS的作用机制,为中西医结合治疗CRS提供科学依据。展开更多
中医药在防治传染病方面具有悠久历史和丰富经验。在抗击新型冠状病毒肺炎(以下简称新冠肺炎)过程中,中医药发挥了不可替代的重要作用,包括“三方三药”在内的系列中药在防控新冠肺炎疫情过程中体现出明确疗效。笔者团队在第一时间开展...中医药在防治传染病方面具有悠久历史和丰富经验。在抗击新型冠状病毒肺炎(以下简称新冠肺炎)过程中,中医药发挥了不可替代的重要作用,包括“三方三药”在内的系列中药在防控新冠肺炎疫情过程中体现出明确疗效。笔者团队在第一时间开展新冠肺炎中西医结合救治工作,建立了融辨病论治、辨证论治与辨靶论治于一体的中医药科学组方创新模式——系统辨靶论治(target-combined holistic treatment of TCM),成功研制出了可有效阻断新冠肺炎重症化的中医药“克冠一号”,同时提出了中医药抗击新冠肺炎“攘外安内”学说,并探索建立了一套中医药防治新突发传染病临床科研攻关模式。为抗击新冠肺炎疫情提供了中医药解决方案。展开更多
The interaction of raltitrexed（RTX） with bovine serum albumin（BSA） was investigated by steady state/lifetime fluorescence spectroscopy and circular dichroism（CD） spectroscopy under the simulative physiological c...The interaction of raltitrexed（RTX） with bovine serum albumin（BSA） was investigated by steady state/lifetime fluorescence spectroscopy and circular dichroism（CD） spectroscopy under the simulative physiological conditions.The results of fluorescence titration reveal that RTX could strongly quench the intrinsic fluorescence of BSA via a static quenching procedure.The obtained binding constant K A of RTX with BSA was 478630 and 44259 L/mol at 298 and 310 K,respectively.According to van＇t Hoff equation,the thermodynamic parameters ΔH,ΔG and ΔS were calculated,indicating that hydrophobic forces were the predominant intermolecular forces in stabilizing the complex.The binding process was a spontaneous process,in which Gibbs free energy change was negative.According to F rster＇s non-radioactive energy transfer theory,the distance r between donor（BSA） and acceptor（RTX） was 3.82 nm,suggesting that the energy transfer from BSA to RTX occurred with high probability.Displacement experiment and the number of binding sites calculation confirmed that RTX could bind to the site-I of BSA.Furthermore,the effects of pH and some metal ions on the interaction of RTX with BSA were also investigated.The results of synchronous fluorescence and CD spectra show that the RTX-BSA binding induced conformational changes in BSA.展开更多
Objectives:To develop a new Chinese medicine(CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome(ARDS)in COVID-19 patients.Methods:A putative ARDS-suppressing drug ...Objectives:To develop a new Chinese medicine(CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome(ARDS)in COVID-19 patients.Methods:A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized,controlled two-arm trial.The two arms of the trial consist of a control therapy(alpha interferon inhalation,50(x g twice daily;and lopinavir/ritonavir,400 and 100 mg twice daily,respectively)and a testing therapy(control therapy plus Keguan-119.4 g twice daily)by random number table at 1:1 ratio with 24 cases each group.After 2-week treatment,adverse events,time to fever resolution,ARDS development,and lung injury on newly diagnosed COVID-19 patients were assessed.Results:An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse events.Based on this result,the study was expanded to include a total of 48 participants(24 cases each arm).The results show that compared with the control arm,the testing arm exhibited a significant improvement in time to fever resolution(P=0.035),and a significant reduction in the development of ARDS(P=0.048).Conclusions:Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients.(Trial registration No.NCT 04251871 at www.clinicaltrials.gov).展开更多
Through complexation reaction of arynyl Fe-S complexes A(μ-p-CH_3C_6H_4C≡CS)(μ- RS)Fe_2(CO)_6 with Co_2(CO)_6, eight mixed cluster complexes B[μ-p-CH_3C_6H_4C_2Co_2(CO)_6S](μ- RS)Fe_2(CO)_6 have been synthesized....Through complexation reaction of arynyl Fe-S complexes A(μ-p-CH_3C_6H_4C≡CS)(μ- RS)Fe_2(CO)_6 with Co_2(CO)_6, eight mixed cluster complexes B[μ-p-CH_3C_6H_4C_2Co_2(CO)_6S](μ- RS)Fe_2(CO)_6 have been synthesized. Reactivity of the complexation reaction is approximately equi- valent to that of the reaction of diarylacetylene with Co_2(CO)_8. Conformational analysis has shown that R groups in complexes A are linked to sulfur atoms by a-and e-bond, whereas that in B only by art e-type of bond.展开更多
文摘慢性鼻-鼻窦炎(chronic rhinosinusitis,CRS)是鼻腔及鼻窦黏膜的慢性炎症,包括慢性鼻-鼻窦炎不伴鼻息肉(chronic rhinosinusitis without nasal polyps,CRSsNP)和慢性鼻-鼻窦炎伴鼻息肉(chronic rhinosinusitis with nasal polyps,CRSwNP)。中医治疗CRS主要包括:辨证论治、专方验方、中成药、针灸、耳穴贴压、中药鼻腔雾化和中药鼻腔冲洗、穴位按摩等;西医治疗主要包括糖皮质激素、抗生素、抗过敏药物、黏液溶解促排剂、手术治疗等。中西医结合治疗是目前治疗CRS的重要手段,但存在以下问题:相关临床文献较少,尚无临床指南,且中医药治疗CRS的作用机制还不明确。今后,需要行多中心、大样本的临床研究,进一步深入探讨中医药治疗CRS的作用机制,为中西医结合治疗CRS提供科学依据。
文摘中医药在防治传染病方面具有悠久历史和丰富经验。在抗击新型冠状病毒肺炎(以下简称新冠肺炎)过程中,中医药发挥了不可替代的重要作用,包括“三方三药”在内的系列中药在防控新冠肺炎疫情过程中体现出明确疗效。笔者团队在第一时间开展新冠肺炎中西医结合救治工作,建立了融辨病论治、辨证论治与辨靶论治于一体的中医药科学组方创新模式——系统辨靶论治(target-combined holistic treatment of TCM),成功研制出了可有效阻断新冠肺炎重症化的中医药“克冠一号”,同时提出了中医药抗击新冠肺炎“攘外安内”学说,并探索建立了一套中医药防治新突发传染病临床科研攻关模式。为抗击新冠肺炎疫情提供了中医药解决方案。
基金Supported by the National Natural Science Foundation of China(No.30973659)
文摘The interaction of raltitrexed（RTX） with bovine serum albumin（BSA） was investigated by steady state/lifetime fluorescence spectroscopy and circular dichroism（CD） spectroscopy under the simulative physiological conditions.The results of fluorescence titration reveal that RTX could strongly quench the intrinsic fluorescence of BSA via a static quenching procedure.The obtained binding constant K A of RTX with BSA was 478630 and 44259 L/mol at 298 and 310 K,respectively.According to van＇t Hoff equation,the thermodynamic parameters ΔH,ΔG and ΔS were calculated,indicating that hydrophobic forces were the predominant intermolecular forces in stabilizing the complex.The binding process was a spontaneous process,in which Gibbs free energy change was negative.According to F rster＇s non-radioactive energy transfer theory,the distance r between donor（BSA） and acceptor（RTX） was 3.82 nm,suggesting that the energy transfer from BSA to RTX occurred with high probability.Displacement experiment and the number of binding sites calculation confirmed that RTX could bind to the site-I of BSA.Furthermore,the effects of pH and some metal ions on the interaction of RTX with BSA were also investigated.The results of synchronous fluorescence and CD spectra show that the RTX-BSA binding induced conformational changes in BSA.
基金the National Administration of Traditional Chinese Medicine Project(No.2020ZYLCYJ05-1)the National Natural Science Foundation of China(Nos.81630100,81721002,81930110)+2 种基金China PLA Biosecurity Project(No.19SWAQ13)China PLA Emergency Project(BWS20J006)the Beijing Administration of Traditional Chinese Medicine Project(Nos.YJ2020-03,SYFY202011)。
文摘Objectives:To develop a new Chinese medicine(CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome(ARDS)in COVID-19 patients.Methods:A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized,controlled two-arm trial.The two arms of the trial consist of a control therapy(alpha interferon inhalation,50(x g twice daily;and lopinavir/ritonavir,400 and 100 mg twice daily,respectively)and a testing therapy(control therapy plus Keguan-119.4 g twice daily)by random number table at 1:1 ratio with 24 cases each group.After 2-week treatment,adverse events,time to fever resolution,ARDS development,and lung injury on newly diagnosed COVID-19 patients were assessed.Results:An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse events.Based on this result,the study was expanded to include a total of 48 participants(24 cases each arm).The results show that compared with the control arm,the testing arm exhibited a significant improvement in time to fever resolution(P=0.035),and a significant reduction in the development of ARDS(P=0.048).Conclusions:Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients.(Trial registration No.NCT 04251871 at www.clinicaltrials.gov).
文摘Through complexation reaction of arynyl Fe-S complexes A(μ-p-CH_3C_6H_4C≡CS)(μ- RS)Fe_2(CO)_6 with Co_2(CO)_6, eight mixed cluster complexes B[μ-p-CH_3C_6H_4C_2Co_2(CO)_6S](μ- RS)Fe_2(CO)_6 have been synthesized. Reactivity of the complexation reaction is approximately equi- valent to that of the reaction of diarylacetylene with Co_2(CO)_8. Conformational analysis has shown that R groups in complexes A are linked to sulfur atoms by a-and e-bond, whereas that in B only by art e-type of bond.
